PARIJS–(BUSINESS WIRE)–Sofinnova Partners, een toonaangevende durfinvesteerder in de levenswetenschappen, heeft vandaag bekendgemaakt dat het fonds Sofinnova Capital VIII is afgesloten met 300 miljoen euro. Daarmee is het streefbedrag van 250 miljoen…
Category: Business
Riassunto: Sofinnova Partners raccoglie 300 milioni di euro in un fondo mirato al settore sanitario
PARIGI–(BUSINESS WIRE)–Sofinnova Partners, importante operatore europeo di venture capital specializzato nel settore delle bioscienze, ha oggi annunciato la chiusura di Sofinnova Capital VIII a 300 milioni di euro, in eccesso rispetto al target inizi…
Novaliq GmbH beruft Dr. Friedrich von Bohlen als Vorsitzenden und Dr. Gerald Cagle als neues Mitglied in den Aufsichtsrat
HEIDELBERG, Deutschland–(BUSINESS WIRE)–Die Novaliq GmbH, ein Unternehmen für pharmazeutische Spezialprodukte mit einer innovativen Drug-Delivery-Plattform zur Formulierung schwerlöslicher aktiver pharmazeutischer Wirkstoffe für Anwendungen in der Ophthalmologie, gab heute bekannt, dass Dr. Friedrich von Bohlen zum Aufsichtsratsvorsitzenden ernannt und Dr. Jerry Cagle in den Aufsichtsrat berufen wurde. Dr. von Bohlen ist seit 1997 im Bereich der Biowissenschaften tätig und bringt 20 Jahre unt
Novaliq GmbH nomme le Dr. Friedrich von Bohlen au poste de président du conseil et le Dr. Gerald Cagle, comme nouveau membre du conseil de surveillance de Novaliq
HEIDELBERG, Allemagne–(BUSINESS WIRE)–Novaliq GmbH, société pharmaceutique spécialisée, dotée d’une plateforme perturbatrice d’administration de médicaments qui transforme les médicaments peu solubles en traitements ophtalmiques efficaces, a annoncé aujourd’hui que le Dr.Friedrich von Bohlen avait été nommé président du conseil de surveillance de la société et que le Dr. Jerry Cagle était devenu membre du conseil. Le Dr. von Bohlen travaille dans le secteur des sciences de la vie depuis 1997
Novaliq GmbH Appoints Friedrich von Bohlen, PhD, as Chairman and Gerald Cagle, PhD, as New Member of Novaliq’s Supervisory Board
HEIDELBERG, Germany–(BUSINESS WIRE)–Novaliq GmbH today announced that Friedrich von Bohlen, PhD, has been appointed Chairman of the company’s Supervisory Board and that Jerry Cagle, PhD, has joined the Board as Member.
Riassunto: Novaliq GmbH nomina il Dr. Friedrich von Bohlen come presidente e il Dr. Gerald Cagle come nuovo membro del Consiglio di sorveglianza di Novaliq
HEIDELBERG, Germania–(BUSINESS WIRE)–Novaliq GmbH, casa farmaceutica specializzata nella ricerca clinica con una piattaforma tecnologica innovativa per il rilascio dei farmaci in grado di trasformare ritrovati poco solubili in terapie efficaci per il settore dell’oftalmologia, ha oggi annunciato che il Dr. Friedrich von Bohlen sarà il nuovo presidente del Consiglio di sorveglianza dell’azienda, mentre il Dr. Jerry Cagle entra a far parte del Consiglio come nuovo membro. Il dottor von Bohlen o
Research and Markets: Ocular Pain – Pipeline Review, Technologies & Forecast Report H2 2015
DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/45plhq/ocular_pain) has announced the addition of the “Ocular Pain – Pipeline Review, H2 2015” report to their offering. The report Ocular Pain – Pipeline Review,…
CareCredit and National Vision Inc. Expand Patient Financing Agreement
COSTA MESA, Calif., & LAWRENCEVILLE, Ga.–(BUSINESS WIRE)–CareCredit and National Vision Inc. Expand Patient Financing Agreement
rhNGF, der biotechnologisch hergestellte Wirkstoff von Dompé gegen neurotrophe Keratopathie, erhält Orphan-Drug-Status von der Europäischen Arzneimittel-Agentur (EMA)
MAILAND–(BUSINESS WIRE)–Der rekombinante humane Nervenwachstumsfaktor (rhNGF) erhält vom „Ausschuss für Arzneimittel für seltene Leiden“ der Europäischen Arzneimittel-Agentur (EMA) den Orphan-Drug-Status bei der Behandlung der neurotrophen Keratopathie. Das von Dompé entwickelte und biotechnologisch hergestellte Molekül basiert auf den Forschungen der Nobelpreisträgerin Rita Levi Montalcini. NGF ist der erste neurotrophe Faktor, der identifiziert und isoliert werden konnte. Er zählt zu den in
rhNGF, la molécula de biotecnología de Dompé para el tratamiento de la queratitis neurotrófica, recibe la designación de medicamento huérfano de la Agencia Europea de Medicamentos
MILÁN–(BUSINESS WIRE)–La empresa biofarmacéutica Dompé ha anunciado hoy que el Comité de Medicamentos Huérfanos de la Agencia Europea de Medicamentos ha designado oficialmente el factor de crecimiento nervioso humano recombinante (rhNFG) – la molécula de biotecnología en investigación desarrollada por Dompé de acuerdo con los estudios de la premio Nobel Rita Levi-Montalcini – como medicamento huérfano para el tratamiento de la queratitis neurotrófica. NGF es el primer factor neurotrófico que
rhNGF, la molécule de Dompé Biotech pour le traitement de la kératite neurotrophique, obtient la désignation de médicament orphelin de l’Agence européenne du Médicament
MILAN–(BUSINESS WIRE)–La société biopharmaceutique Dompé a annoncé aujourd’hui que le Comité des Médicaments orphelin de l’Agence européenne du Médicament (EMA) a désigné officiellement le facteur de croissance du nerf humain recombinant (rhNGF) – la molécule biotechnologique expérimentale développée par Dompé sur la base des recherches effectuées par la lauréate du Prix Nobel Rita Levi Montalcini – comme étant un médicament orphelin pour le traitement de la kératite neurotrophique. Le facteu
Clearside Biomedical, Inc. Completes $20 Million Series C Financing
ALPHARETTA, Ga.–(BUSINESS WIRE)–Clearside Biomedical, a clinical-stage biopharmaceutical company developing innovative first-in-class drug therapies for diseases of the eye, announces completion of $20 million Series C financing.
rhNGF, the Dompé Biotech Molecule for the Treatment of Neurotrophic Keratitis, Receives Orphan Drug Designation from the European Medicines Agency
MILAN–(BUSINESS WIRE)–The Dompé biopharmaceutical company announced today that the Committee for Orphan Medicinal Products of the European Medicines Agency (EMA) has officially designated recombinant human Nerve Growth Factor (rhNGF) – the investigational biotech molecule developed by Dompé based on research by Nobel Laureate Rita Levi Montalcini – as an orphan drug for the treatment of neurotrophic keratitis. NGF is the first neurotrophic factor to be identified and purified, and represents
rhNGF, la molecola biotecnologica Dompé per la cura della cheratite neurotrofica, designato farmaco orfano dalla European Medicines Agency
MILANO–(BUSINESS WIRE)–L’azienda biofarmaceutica Dompé annuncia che il Comitato per i Farmaci Orfani dell’EMA (European Medicines Agency) ha ufficialmente designato rhNGF, la molecola biotecnologica sperimentale messa a punto dalla ricerca Dompé sulla scorta degli studi del Premio Nobel per la Medicina Rita Levi Montalcini, come farmaco orfano per il trattamento della cheratite neurotrofica. NGF (Nerve Growth Factor) è il primo fattore neurotrofico a essere identificato e purificato e, oggi,
CoreSource and Liazon Partner to Launch TPA Private Exchange Solution
LAKE FOREST, Ill.–(BUSINESS WIRE)–CoreSource, a national health benefits administrator, & Liazon, operator of industry-leading private benefits exchange Bright Choices®, creates a new third-party administrator (TPA) private exchange.
Ophthotech Corporation to Present at the Oppenheimer 26th Annual Healthcare Conference
NEW YORK–(BUSINESS WIRE)–Ophthotech announced today that David R. Guyer will present an overview of the Company at the Oppenheimer 26th Annual Healthcare Conference in New York City on December 8, 2015 at 8:35 a.m. ET.
RetroSense Therapeutics to Present at Upcoming Healthcare Conferences
ANN ARBOR, Mich.–(BUSINESS WIRE)–RetroSense Therapeutics Chief Executive Officer Sean Ainsworth will present at the 27th Annual Piper Jaffray Healthcare Conference and the Genetic RX Conference.
ACADIA Pharmaceuticals Appoints Srdjan (Serge) Stankovic, M.D., M.S.P.H., as Executive Vice President, Head of Research and Development
SAN DIEGO–(BUSINESS WIRE)–ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today…
ACADIA Pharmaceuticals Appoints Edmund P. Harrigan, M.D., to Board of Directors
SAN DIEGO–(BUSINESS WIRE)–ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today…
Research and Markets: Choroidal Neovascularization – Pipeline Analysis & Review, H2 2015
DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/kxvtp3/choroidal) has announced the addition of the “Choroidal Neovascularization – Pipeline Review, H2 2015” report to their offering. The report, Choroidal Neov…